Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases.

Sarah Jenkins Wei Zhang Seth M Steinberg Darryl Nousome Nicole Houston Xiaolin Wu Terri S Armstrong Eric Burton DeeDee K Smart Ritu Shah Cody J Peer Brett Mozarsky Oluwatobi Arisa William Douglas Figg Tito R Mendoza Elizabeth Vera Priscilla Kaliopi Brastianos Scott L Carter Mark R Gilbert Carey K Anders Caitriona Cahir Carol Tweed Karen Lisa Smith Imran Khan Stanley Lipkowitz Patricia S Steeg Alexandra S Zimmer

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Metronomic TMZ in combination with standard dose T-DM1 shows low-grade toxicity and potential activity in secondary prevention of HER2+ brain metastases.

Keyphrases

brain metastases
low grade
small cell lung cancer
positive breast cancer
high grade
oxidative stress
type diabetes
glycemic control
risk assessment
skeletal muscle